Objectives {1}
NASH, T2DM, HCV infection, HBV infection
TYPE 2 DIABETES MELLITUS, ALCOHOL-RELATED LIVER DISEASE, PORTAL HYPERTENSION
The 1366.0021 trial is a randomised, double-blind, placebo-controlled, exploratory trial assessing the effects of two different doses of BI 685509 on portal hypertension after 24 weeks of treatment in patients with CSPH in alcohol-related liver disease. The 1366.0029 trial is a randomised, open-label, parallel-group, exploratory trial assessing the effects of BI 685509 on portal hypertension after 8 weeks of treatment in patients with CSPH due to HCV infection, HBV infection or NASH and of the combination of BI 685509 and empagliflozin in patients with CSPH due to NASH and with type 2 diabetes mellitus (T2DM).